US5324571083 - Common Stock

Taking everything into account, **LLY** scores **6** out of 10 in our fundamental rating. **LLY** was compared to 198 industry peers in the **Pharmaceuticals** industry. While **LLY** has a great profitability rating, there are quite some concerns on its financial health. **LLY** has a correct valuation and a medium growth rate.

In the past year **LLY** was profitable.

In the past year **LLY** had a positive cash flow from operations.

In the past 5 years **LLY** always reported a positive cash flow from operatings.

Measured over the past 3 years, the **Average Return On Invested Capital** for **LLY** is above the industry average of **16.40%**.

The last **Return On Invested Capital** (**24.14%**) for **LLY** is above the 3 year average (**20.29%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 8.19% | ||

ROE | 48.65% | ||

ROIC | 24.14% |

ROA(3y)10.75%

ROA(5y)13.34%

ROE(3y)56.48%

ROE(5y)119.66%

ROIC(3y)20.29%

ROIC(5y)19.04%

In the last couple of years the **Profit Margin** of **LLY** has remained more or less at the same level.

In the last couple of years the **Operating Margin** of **LLY** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 30.26% | ||

PM (TTM) | 15.36% | ||

GM | 79.25% |

OM growth 3Y2.73%

OM growth 5Y2.37%

PM growth 3Y-15.26%

PM growth 5Y0.42%

GM growth 3Y0.68%

GM growth 5Y0.26%

Compared to 1 year ago, **LLY** has about the same amount of shares outstanding.

Compared to 5 years ago, **LLY** has less shares outstanding

A Debt/Equity ratio of **1.70** is on the high side and indicates that **LLY** has dependencies on debt financing.

Looking at the **Debt to Equity ratio**, with a value of **1.70**, **LLY** is doing worse than **79.49%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.7 | ||

Debt/FCF | N/A | ||

Altman-Z | 9.25 |

ROIC/WACC2.67

WACC9.04%

A Current Ratio of **0.94** indicates that **LLY** may have some problems paying its short term obligations.

With a **Current ratio** value of **0.94**, **LLY** is not doing good in the industry: **87.69%** of the companies in the same industry are doing better.

Looking at the **Quick ratio**, with a value of **0.73**, **LLY** is doing worse than **85.64%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 0.94 | ||

Quick Ratio | 0.73 |

The earnings per share for **LLY** have decreased strongly by **-21.88%** in the last year.

Measured over the past 5 years, **LLY** shows a small growth in **Earnings Per Share**. The EPS has been growing by **2.60%** on average per year.

Looking at the last year, **LLY** shows a quite strong growth in **Revenue**. The Revenue has grown by **19.56%** in the last year.

Measured over the past years, **LLY** shows a quite strong growth in **Revenue**. The Revenue has been growing by **9.69%** on average per year.

EPS 1Y (TTM)-21.88%

EPS 3Y-7.29%

EPS 5Y2.6%

EPS growth Q2Q19.14%

Revenue 1Y (TTM)19.56%

Revenue growth 3Y11.62%

Revenue growth 5Y9.69%

Revenue growth Q2Q28.1%

Based on estimates for the next years, **LLY** will show a quite strong growth in **Revenue**. The Revenue will grow by **15.25%** on average per year.

EPS Next Y99.22%

EPS Next 2Y70.81%

EPS Next 3Y57.29%

EPS Next 5Y36.83%

Revenue Next Year22.92%

Revenue Next 2Y23.93%

Revenue Next 3Y22.03%

Revenue Next 5Y15.25%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

A **Price/Earnings** ratio of **115.83** indicates a quite expensive valuation of **LLY**.

Based on the **Price/Earnings** ratio, **LLY** is valued a bit cheaper than 79.49% of the companies in the same industry.

The average S&P500 **Price/Earnings** ratio is at **25.20**. **LLY** is valued rather expensively when compared to this.

The **Price/Forward Earnings** ratio is **58.14**, which means the current valuation is very expensive for **LLY**.

Based on the **Price/Forward Earnings** ratio, **LLY** is valued a bit cheaper than the industry average as 77.44% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 115.83 | ||

Fwd PE | 58.14 |

75.90% of the companies in the same industry are more expensive than **LLY**, based on the **Enterprise Value to EBITDA** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 61.69 |

The **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

The excellent profitability rating of **LLY** may justify a higher PE ratio.

PEG (NY)1.17

PEG (5Y)44.63

EPS Next 2Y70.81%

EPS Next 3Y57.29%

With a yearly dividend of 0.70%, **LLY** is not a good candidate for dividend investing.

With a **Dividend Yield** of **0.70**, **LLY** pays less dividend than the S&P500 average, which is at **2.45**.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.7% |

On average, the dividend of **LLY** grows each year by **14.87%**, which is quite nice.

Dividend Growth(5Y)14.87%

Div Incr Years9

Div Non Decr Years19

DP77.65%

EPS Next 2Y70.81%

EPS Next 3Y57.29%

**ELI LILLY & CO**

NYSE:LLY (4/24/2024, 10:29:03 AM)

**732.04**

**-13.65 (-1.83%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap696.00B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.7% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 115.83 | ||

Fwd PE | 58.14 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.17

PEG (5Y)44.63

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 8.19% | ||

ROE | 48.65% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 30.26% | ||

PM (TTM) | 15.36% | ||

GM | 79.25% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.53

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.7 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 0.94 | ||

Quick Ratio | 0.73 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-21.88%

EPS 3Y-7.29%

EPS 5Y

EPS growth Q2Q

EPS Next Y99.22%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)19.56%

Revenue growth 3Y11.62%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y